Literature DB >> 9605083

Repair of nonsevere rheumatic aortic valve disease during other valvular procedures: is it safe?

J M Bernal1, M Fernández-Vals, J M Rabasa, F Gutiérrez-García, C Morales, J M Revuelta.   

Abstract

OBJECTIVE: To investigate the long-term performance of aortic valve repair, we analyzed the results obtained in a 22-year period in patients who underwent repair of nonsevere rheumatic aortic valve disease during other valvular procedures.
METHODS: Fifty-three patients (mean 40 +/- 11.6 years of age) with predominant rheumatic mitral valve disease had concomitant aortic valve disease in association with serious tricuspid valve disease in 25 of them. Preoperatively, aortic valve disease was considered moderate in 47.2% of the patients and mild in 52.8%. All patients underwent reparative techniques of the aortic valve (free edge unrolling, 44; subcommissural annuloplasty, 40; commissurotomy, 36) at the time of mitral or mitrotricuspid valve surgery. The completeness of follow-up during the closing interval was 100%, with a mean follow-up of 18.8 years (range 8 to 22.5 years).
RESULTS: Hospital mortality rate was 7.5%. Of 49 surviving patients, 26 (53.1%) died during late follow-up. The actuarial survival curve including hospital mortality was 35.4% +/- 8.7% at 22 years. For patients who underwent mitral and aortic valve surgery, the actuarial survival curve at 22 years was 32.3% +/- 13%, whereas for patients who had a triple-valve operation the survival was 37.0% +/- 10.1% (p = 0.07). Twenty-five patients underwent an aortic prosthetic valve replacement. Actuarial free from aortic structural deterioration and valve-related complications at 22 years was 25.3% +/- 9.3% and 12.7% +/- 4.8%, respectively.
CONCLUSIONS: Long-term functional results of reparative procedures of nonsevere aortic valve disease in patients with predominant rheumatic mitral valve disease have been inadequate at 22 years of follow-up. According to these data, conservative operations for rheumatic aortic valve disease do not seem appropriate.

Entities:  

Mesh:

Year:  1998        PMID: 9605083     DOI: 10.1016/S0022-5223(98)70413-1

Source DB:  PubMed          Journal:  J Thorac Cardiovasc Surg        ISSN: 0022-5223            Impact factor:   5.209


  3 in total

Review 1.  World Heart Federation criteria for echocardiographic diagnosis of rheumatic heart disease--an evidence-based guideline.

Authors:  Bo Reményi; Nigel Wilson; Andrew Steer; Beatriz Ferreira; Joseph Kado; Krishna Kumar; John Lawrenson; Graeme Maguire; Eloi Marijon; Mariana Mirabel; Ana Olga Mocumbi; Cleonice Mota; John Paar; Anita Saxena; Janet Scheel; John Stirling; Satupaitea Viali; Vijayalakshmi I Balekundri; Gavin Wheaton; Liesl Zühlke; Jonathan Carapetis
Journal:  Nat Rev Cardiol       Date:  2012-02-28       Impact factor: 32.419

2.  Natural History of Aortic Regurgitation following Percutaneous Mitral Valvuloplasty.

Authors:  Mohammadali Sadr-Ameli; Mona Heidarali; Sedigheh Saedi; Tehereh Saedi; Ata Firoozi; Mohsen Madani; Hooman Bakhshandeh
Journal:  Res Cardiovasc Med       Date:  2013-02-24

3.  Aortic valve repair for the treatment of rheumatic aortic valve disease: a systematic review and meta-analysis.

Authors:  Meng Zhao; Yihu Tang; Luo Li; Yawei Dai; Jieyu Lu; Xiang Liu; Jingxin Zhou; Yanhu Wu
Journal:  Sci Rep       Date:  2022-01-13       Impact factor: 4.379

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.